Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silexan in mild to moderate major depressive episode
ISRCTN36202964Phase 3Completed
- Sponsor
- Schwabe Group
- Start
- Oct 2020
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Silexan, Sertraline and Placebo (3 arms). Primary endpoint: Change in depression severity by MADRS total score. Started Oct 2020; status: completed.
02
Drugs
Silexansertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN36202964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36202964.